Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels W.C.J. van de Donk, María‐Victoria Mateos, Philippe Moreau, Melitios-Athanasios Dimopoulos, Michel Delforge, Paula Rodríguez‐Otero, Jesús F. San Miguel, Kwee Yong, Francesca Gay, Hermann Einsele, Roberto Mina, Jo Caers, Christoph Driessen, Pellegrino Musto, Sonja Zweegman, Monika Engelhardt, Gordon Cook, Katja Weisel, Annemiek Broijl, Meral Beksaç, Jelena Bila, Fredrik Schjesvold, Michèle Cavo, Roman Hájek, Cyrille Touzeau, Mario Boccadoro, Pieter Sonneveld
Topics & Concepts
Cytokine release syndromeMedicineTocilizumabAdverse effectMultiple myelomaChimeric antigen receptorImmunologyAnakinraCytokineAntibodyCytokine stormImmune systemImmunotherapyPharmacologyInternal medicineCoronavirus disease 2019 (COVID-19)Rheumatoid arthritisDiseaseInfectious disease (medical specialty)CAR-T cell therapy researchNanowire Synthesis and ApplicationsNanofabrication and Lithography Techniques